Select country change
Shopping cart (0 , 0,00 ) Menu Search
Manufactured by BioVendor

hsa-miR-93-5p miREIA

  • Regulatory status:RUO
  • Type:miREIA – miRNA enzyme immunoassay
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price

New RDM0002H 96 wells (1 kit)
PubMed Product Details
Technical Data


miREIA – miRNA enzyme immunoassay


Whole blood

Sample Requirements

10 µl/well


Store the complete kit at 2 – 8 °C. Under these conditions, all components are stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

12.5 – 0.39 amol/μl

Limit of Detection

0.13 amol/μl

Intra-assay (Within-Run)

n = 8,
CV = 8.4%

Inter-assay (Run-to-Run)

n = 5,
CV = 9.3%

Spiking Recovery


Dilutation Linearity




  • It is intended for research use only
  • The total assay time is less than 2.5 hours
  • The kit measures hsa-miR-93-5p isolated from human blood
  • Assay format is 96 wells
  • Standard is synthetic miRNA-based
  • Components of the kit are provided ready to use, concentrated or dried

Research topic

Cardiovascular disease, Oncology, Renal disease

References to Summary

References to miR-93-5p

  • SUETA, Aiko, et al. Differential expression of exosomal miRNAs between breast cancer patients with and without recurrence. Oncotarget, 2017, 8.41: 69934.
  • LI, Nana, et al. MiR-106b and miR-93 regulate cell progression by suppression of PTEN via PI3K/Akt pathway in breast cancer. Cell Death & Disease, 2017, 8.5: e2796.
  • WANG, Shi Jun, et al. MicroRNA 93 5p increases multidrug resistance in human colorectal carcinoma cells by downregulating cyclin dependent kinase inhibitor 1A gene expression. Oncology Letters, 2017, 13.2: 722-730.
  • GAMBARI, Roberto, et al. Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: Νew trends in the development of miRNA therapeutic strategies in oncology. International journal of oncology, 2016, 49.1: 5-32.
  • HE, Yu; YU, Bo. MicroRNA 93 promotes cell proliferation by directly targeting P21 in osteosarcoma cells. Experimental and Therapeutic Medicine, 2017, 13.5: 2003-2011.
  • OHTA, Katsuya, et al. MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A. Oncotarget, 2015, 6.5: 3211.
  • CHEN, Rui, et al. MicroRNA-93 promotes the malignant phenotypes of human glioma cells and induces their chemoresistance to temozolomide. Biology open, 2016, 5.6: 669-677.
  • JOHN, F. O., et al. miRNA-93-5p and other miRNAs as predictors of coronary artery disease and STEMI. International journal of cardiology, 2016, 224: 310-316.
  • ULBING, M., et al. MicroRNAs 223-3p and 93-5p in patients with chronic kidney disease before and after renal transplantation. Bone, 2017, 95: 115-123.
Related Products